Annabel Kartal AllenNovember 14, 2025

The potential of digital twin technology is growing within the clinical trials landscape. Image credit: Gorodenkoff via ShutterStock.com.

In recent years, automation and artificial intelligence (AI) have been huge trends within the clinical trials landscape, as companies look to incorporate such technologies to optimise their operational efficiency.

Alongside the burgeoning growth of AI in the sector, digital twin technology is emerging as a powerful tool – one that could help shape the future of clinical trials.

This technology, which has its roots in the factory setting, could one day allow clinical trial operators to create a dynamic, virtual replica of a patient’s physiology. In theory, this could allow operators to predict how a patient might respond to a treatment by harnessing real-world data.

According to Dimitris Christodoulou, global business lead in digital health at Roche, the true endgame for digital twins – simulating a patient’s complex physiology – is “still on the horizon”.

The current potential of digital twins

While the digital twin concept has progressed since its first introduction into the clinical trials landscape, Christodoulou notes that the focus and priority for the technology now should be on delivering immediate value.

“The potential for immediate breakthroughs is more related to Operational and ‘behavioural’?twins,” he stated.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Learn more about Strategic Intelligence

“Digital twins will take first ground in this context, as its use case delivers proven efficiency today. Then, the concept may be brought to patients and other scenarios,” Christodoulou added.

Currently, digital twins are being used in pilot and exploratory settings to optimise trial design, as they can simulate millions of scenarios to pinpoint where costs can be saved and time can be reduced.

These models can also be used to predict if an individual has a “high probability of dropping compliance or dropping off within the next 30 days”, according to Christodoulou.

To get the most out of a digital twin, Christodoulou believes that they will require input from a diverse range of sources, including everything from “multi-omics data, demographics and electronic health records to real-time data from wearables and recruitment channels”.

Following the incorporation of these efforts, Christodoulou predicts that the industry could see a robust twin or tool in the next five-to-seven years.

Digital twins yet to overcome hurdles

When employing digital twins in the clinical trials landscape, the industry’s lack of full mechanistic understanding of disease can present a challenge, as some information cannot be translated from the molecular to the organism level.

However, a hybrid approach could be the answer, as this allows companies to harness established mechanistic level information while bridging the gaps using AI.

“While you might not fully comprehend the reasoning behind the suggestions, they could still prove useful,” Christodoulou said.

Alongside issues at a molecular level, data can also present a hurdle for digital twin development. “There is still significant data fragmentation across the ecosystem, leading to the creation of models which end up using information that is simply not useful,” Christodoulou iterated.

Companies developing this technology will also have to overcome ethical and regulatory concerns, which, in part, centre around the use of historical data.

“It would be easy for these biases to creep into any digital twin solution, so there is still a lot to uncover to ensure fairness and equity,” Christodoulou commented.

Though there is still some way to go before digital twins reach their true end-game, Christodoulou believes that the industry is “approaching the horizon where we will see robust, scalable digital twin tools for clinical trial optimisation”.

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.

Sign up

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now